The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

<div>The sensitivity analysis. (a) Sensitivity analysis for hazard ratio (HR) of overall survival (OS). (b) Sensitivity analysis for hazard ratio (HR) of progression-free survival (PFS).</div>

Journal of Oncology

fig4

Figure 4

Figure 4: The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer 

Figure 4 | The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer 